ASCO 2023 | DEPEND: nivolumab with chemotherapy and response-stratified CRT in HNSCC

Ari Rosenberg, MD, University of Chicago, Chicago, IL, describes the trial design of the Phase II DEPEND trial (NCT03944915), which assessed neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). Patients, who a deep response i.e. a tumor shrinkage of more than 50%, received reduced chemoradiation, whereas patients with a suboptimal response received the standard dose. The primary endpoint was deep response rate. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.